This study is accepting new patients by invitation only
Long-term Safety Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)
a study on Peanut Allergy
Peanut AllergyAR101Characterized Peanut AllergenOIT (oral immunotherapy)AllergyPeanut-Allergic ChildrenPeanut-Allergic AdultsDesensitizationCPNA (Characterized Peanut Allergen)HypersensitivityPeanut Hypersensitivity
- accepting new patients by invitation only
- Start Date
- Completion Date
- Aimmune Therapeutics, Inc.
- Click to request more information about this study.
- Phase 3
- Study Type
- Last Updated